SP Gonadotropin 5000IU

Human Chorionic Gonadotropin is a strong polypeptide hormone present in pregnant women, primarily utilized for therapeutic purposes such as addressing Cryptorchidism, female infertility, hypogonadism (low testosterone), and weight loss.

Additionally, HCG is frequently employed by anabolic steroid users as a complementary agent during or after steroid cycles. When steroids are used, the purpose of HCG supplementation is to alleviate hormonal suppression caused by the steroids. Following steroid use, HCG helps to enhance or optimize recovery.

One notable effect of HCG in contemporary practice is its role as a weight-loss aid. The HCG diet has gained popularity in Western medicine, yet its overall effectiveness has stirred substantial debate. Both the American Medical Association and the American Society of Bariatric Physicians have expressed strong opposition to the HCG diet, stating that any observed weight loss is primarily a result of the significant calorie restriction involved in the program, which often allows only 500 calories per day. Furthermore, HCG does not activate thyroid function, does not stimulate beta-2 receptors, does not suppress appetite, and lacks characteristics commonly associated with thermogenic or fat-burning agents. Despite various reports of success from physicians using the HCG diet, the underlying issue of starvation raises concerns over its sustainability and health implications as a long-term approach. Currently, there is no compelling evidence to suggest that weight loss attributed to the HCG diet would not occur with the same restrictive caloric intake without HCG. The debate surrounding this diet is expected to continue for the foreseeable future.

For anabolic steroid users, the effects of HCG can be categorized into two main areas: post-cycle therapy (PCT) and on-cycle use. Anabolic steroid use typically leads to a suppression of natural testosterone production, with the extent depending on the specific steroids and dosages involved. After ceasing steroid use, testosterone production may gradually resume, provided there were no pre-existing low testosterone conditions or significant damage to the hypothalamic-pituitary-testis axis (HPTA). However, this natural recovery can be slow, resulting in very low testosterone levels and associated symptoms, which can be particularly troublesome and may lead to muscle loss due to elevated cortisol levels in the absence of testosterone. Consequently, many steroid users implement PCT plans to facilitate recovery and restore testosterone levels more swiftly, allowing for adequate testosterone availability for bodily functions during this recovery phase.

Several PCT regimens exist, often including selective estrogen receptor modulators (SERMs) like Nolvadex (Tamoxifen Citrate) and/or Clomid (Clomiphene Citrate). Many users have found that initiating a PCT plan with HCG prior to SERM introduction can enhance overall recovery. In this context, HCG mimics luteinizing hormone (LH) and readies the body for subsequent SERM therapy, thus promoting a more efficient recovery process.

The second beneficial aspect of HCG for anabolic steroid users is its use during steroid cycles. Steroid use can lead to testicular atrophy due to suppressed testosterone production. By supplementing with HCG while on steroids, individuals can maintain testicular size. While this effect is purely cosmetic with no obvious tactical advantage, it may provide some benefit, as the presence of exogenous LH may facilitate an easier recovery once steroid use concludes. However, a significant risk exists; the body can easily develop dependence on HCG for its LH needs. While dependence on anabolic steroids is less likely, dependence on HCG can become a concern. For those with legitimate low testosterone conditions, this is typically not an issue. However, for non-low testosterone patients, strict regulation and monitoring of HCG use during cycles are essential to prevent LH dependency. Many steroid users have unfortunately caused significant harm to their bodies through excessive HCG use compared to anabolic steroids. Although responsible on-cycle HCG use can assist in achieving a smoother recovery, careful management is paramount.

HCG is used for various reasons, leading to multiple dosing protocols. For ovarian stimulation (as a fertility aid), HCG is administered at a specific moment during the menstrual cycle at doses ranging from 5,000 to 10,000 IU. For treating low testosterone, regimens can last from six weeks to a full year. Short-term plans typically involve administering 500 to 1,000 IU three times weekly for three weeks, followed by 500 to 1,000 IU two times per week for an additional three weeks. Long-term dosing usually falls around 4,000 IU, given three times a week for six to nine months, followed by three months at a reduced dose of 2,000 IU three times per week.

For anabolic steroid users utilizing HCG during their cycles, typical dosing is 250 IU every 4-5 days, which is deemed standard and sufficient to achieve the desired results without risking future natural testosterone production.

For PCT, two primary protocols have been established for HCG use. The first involves administering 1,500 to 4,000 IU every 3-4 days for two to three weeks before beginning SERM therapy. The second, potentially more effective option, is to use HCG daily at 500 to 1,000 IU for ten consecutive days before starting SERM therapy.

Timing is crucial when incorporating HCG into a PCT regimen. If the steroid cycle concludes with long-acting esters, HCG treatment should start ten days after the final injection, followed by SERM therapy once HCG is discontinued. Conversely, if the cycle ends with short-acting esters, HCG therapy should commence three days after the last injection, followed by SERM therapy once HCG is concluded.